Essential website updates between 07:00-07:15am CET 21 March 2025 may cause disruption.
Approvals are a subset of commitments for which funding availability and programme performance has been assessed as satisfactory. Only such approved amounts can be disbursed subject to all other conditions for disbursement being met by the countries. Approvals are typically granted for the current year and one further year.
Commitments represent endorsements of multi-year programme budgets made by the Gavi Board, Executive Committee or the CEO. These endorsements do not constitute a liability to pay but instead send a positive signal that Gavi intends to fund a programme over its entire life span subject to performance and availability of funds.
Disbursements by 'Programme Year' in the graph shows the payments made from 2020 up to the date of the report. The payments are shown by the programme year to which they relate irrespective of the calendar year in which they were made. The programme year is the year in which the relevant vaccine/cash programme is being implemented.
Annual figures may reflect negative values due to refunds from previous years or allocation of prepayments to reflect actual apportionment by country.
Disclaimer: the boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of Gavi, the Vaccine Alliance concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
This Gavi country data is made available under the Creative Commons BY 4.0 license: https://creativecommons.org/licenses/by/4.0/
Vaccines will be delivered to countries affected by the upsurge of mpox that continues to constitute a Public Health Emergency of International Concern (PHEIC). The first shipment of 11, 200 doses arrived in Nigeria on 20 December.
Unitaid and Gavi establish new partnership to improve access to cervical cancer prevention
Unitaid and Gavi will pilot integrated cervical cancer screening and treatment with HPV vaccination programs through a new partnership.
Nigeria receives malaria vaccines ahead of roll-out
In a historic step toward combating malaria in Nigeria, the first-ever malaria vaccines have been delivered to the Government of Nigeria, thanks to efforts by Gavi, the Vaccine Alliance, UNICEF and WHO.
Nigeria to vaccinate 7.7 million girls against leading cause of cervical cancer
Nigeria today introduced the human papillomavirus (HPV) vaccine into its routine immunisation system, aiming to reach 7.7 million girls. This is the largest number in a single round of HPV vaccination in the African region in a vaccination drive…
Over the next few years, Gavi, the Vaccine Alliance and partners will focus efforts to revitalise access to the human papillomavirus (HPV) vaccine to reach 86 million adolescent girls, rapidly recover and improve coverage, and help build…
Funding disbursed to boost vaccine access in humanitarian and fragile settings
The funding will enable international and local civil society organisations to complement public health service efforts by accessing communities not reached by government services, such as in cross-border settings and conflict zones, across the…
Gavi launches new learning initiative to address the final barriers to immunisation equity
Reaching the millions of “zero-dose” children who have yet to receive a single vaccine represents one of the final – and most complex – barriers to overcome in the push for global immunisation equity
Today’s launch marks the introduction of the rotavirus vaccine, which protects against rotavirus-related diarrhoeal disease, into Nigeria’s routine immunisation programme.
Compulsory vaccination helps conquer fears in Nigeria
Mandatory vaccination policy introduced by the Federal Government of Nigeria in all its public institutions has contributed to an increase in the number of vaccinated people.
Name | Source | Date |
---|---|---|
Total population | United Nations, World Population Prospects (UN WPP), July 2024 release. | 2024-07-11 |
Birth cohort (Total number of live births) | United Nations, World Population Prospects (UN WPP), July 2024 release. | 2024-07-11 |
Surviving infants (# of children surviving to 1 year) | United Nations, World Population Prospects (UN WPP), July 2024 release. | 2024-07-11 |
Infant mortality rate (deaths < 1 year per 1000 births) | UN Inter-agency Group for Child Mortality Estimation (UN IGME), March 2024 release. | 2024-04-15 |
Child mortality rate (deaths < 5 years per 1000 births) | UN Inter-agency Group for Child Mortality Estimation (UN IGME), March 2024 release. | 2024-04-15 |
GNI per capita, Atlas method (current US$) | World Bank national accounts data, and OECD National Accounts data files, July 2024 release. | 2024-07-01 |
Number of zero-dose children | WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), July 2024 release; figures calculated using number of surviving infants from UN World Population Prospects (UN WPP) | 2024-07-15 |
% reduction in number of zero-dose children, 2019-2023 | WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), July 2024 release; figures calculated using number of surviving infants from UN World Population Prospects (UN WPP) | 2024-07-15 |
DTP1/DTP3/MCV1 coverage (%) | WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), July 2024 release. | 2024-07-15 |
Drop out from DTP1 to DTP3 | WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), July 2024 release | 2024-07-15 |
Drop out from DTP1 to last routine dose of MCV | WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), July 2024 release. | 2024-07-15 |
Geographic equity of DTP3 coverage: DTP3 coverage in the 20% of districts with lowest coverage | WHO/UNICEF Joint Reporting Form (JRF), July 2024 release. | 2024-07-05 |